Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
All‐cause mortality at last · people with liver metastases
Summary of Findings Table ‐ Electrocoagulation in combination with… may leads to lower all‐cause mortality at last compared with control (vehicle solution of allopurinol by mouth) (low certainty).
1 finding from 1 review
Post‐operative deaths · people with liver metastases
It is very uncertain whether summary of Findings Table ‐ Electrocoagulation in combination with… changes post‐operative deaths compared with control (vehicle solution of allopurinol by mouth) (very low certainty).
1 finding from 1 review
Other adverse events and complications · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
Water samples with fluoride concentration below the acceptable range · Artificially fluoridated public water supply in Brazilian cities (water samples under external control)
In the Northeast Brazilian region, a pooled 79.7% of water samples had fluoride below the acceptable range; ungraded.
2 findings from 1 review
Water samples with fluoride concentration above the acceptable range · Artificially fluoridated public water supply in Brazilian cities (water samples under external control)
In the Southeast Brazilian region, a pooled 11.5% of water samples had fluoride above the acceptable range; ungraded.
2 findings from 1 review
Water samples with fluoride concentration outside the acceptable range · Artificially fluoridated public water supply in Brazilian cities (water samples under external control)
In Brazilian cities using external control, more than half of artificially fluoridated public water supply samples (pooled 56.6%, 95% CI 45.5 to 67.3) had fluoride concentrations outside the acceptable range, with very high heterogeneity (I2=99.5%); ungraded.
3 findings from 1 review
Failure to clear liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to clear liver metastases · people with liver metastases
1 finding from 1 review
Recurrence of liver metastases local progression · people with liver metastases
It is very uncertain whether microwave coagulation changes recurrence of liver metastases local progression compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Recurrence of liver metastases distant recurrence · people with liver metastases
It is very uncertain whether microwave coagulation changes recurrence of liver metastases distant recurrence compared with radiofrequency ablation (very low certainty).
1 finding from 1 review
Failure to clear liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Dimethylfumarate (Direct evidence; 2 RCTs; 2307 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to lower dimethylfumarate (Direct evidence; 2 RCTs; 2307 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Dimethylfumarate (Direct evidence; 2 RCTs; 2307 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to lower dimethylfumarate (Direct evidence; 2 RCTs; 2307 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Dimethylfumarate (Direct evidence; 2 RCTs; 2300 participants) · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention showed no clear difference in dimethylfumarate (Direct evidence; 2 RCTs; 2300 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Dimethylfumarate (Direct evidence; 2 RCTs; 2300 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
The intervention showed no clear difference in dimethylfumarate (Direct evidence; 2 RCTs; 2300 participants) (low certainty).
1 finding from 1 review
Cardiovascular and metabolic event frequency (12 months) (Number of strokes, myocardial infarctions and hospitalisations for heart failure) · weight reduction in obesity to improve survival in women with endometrial cancer
Summary of findings table ‐ Lifestyle intervention showed no clear difference in cardiovascular and metabolic event frequency (6 months) compared with usual care compared to placebo (low certainty).
1 finding from 1 review